Voyager Therapeutics (VYGR) Total Liabilities (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Total Liabilities data on file, last reported at $45.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 43.31% year-over-year to $45.7 million; the trailing twelve-month figure through Mar 2026 stood at $45.7 million (down 43.31% YoY), and the FY2025 full-year result was $56.2 million, down 39.76% from the prior year.
• Total Liabilities eased to $45.7 million in Q1 2026, from $56.2 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $148.3 million in Q1 2022 to a low of $45.7 million in Q1 2026.
• A 5-year average of $99.8 million and a median of $100.8 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities jumped 46.05% in 2022 and plunged 43.31% in 2026, its largest moves.
• Tracing VYGR's Total Liabilities over 5 years: stood at $100.3 million in 2022, then advanced by 14.58% to $115.0 million in 2023, then declined by 18.85% to $93.3 million in 2024, then tumbled by 39.76% to $56.2 million in 2025, then slipped by 18.76% to $45.7 million in 2026.
• Business Quant data shows VYGR's Total Liabilities at $45.7 million in Q1 2026, $56.2 million in Q4 2025, and $68.5 million in Q3 2025.